Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Recruiting 10Completed 7Active not recruiting 5Withdrawn 4Terminated 4Unknown 3Not yet recruiting 1No longer available 1

Sponsor Class

OTHER 2NETWORK 1INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 4Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation 1

Interventions

Carboplatin 40Cisplatin 37Pemetrexed 33Radiotherapy 23Paclitaxel 22pembrolizumab 20durvalumab 19Docetaxel 19Gemcitabine 18Nivolumab 15Radiosurgery 14Etoposide 13atezolizumab 11Erlotinib Hydrochloride 11Taxes 8Magnetic Resonance Spectroscopy 8Drug Therapy 8Bevacizumab 8Cyclophosphamide 7Platinum 6Gefitinib 6Surveys and Questionnaires 5Biopsy 5130-nm albumin-bound paclitaxel 51,2-diaminocyclohexaneplatinum II citrate 5sotorasib 4Ramucirumab 4Radiation 4Immunotherapy 4Fluorodeoxyglucose F18 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Withdrawn × sotorasib × Thoracic × Clear all
NCT06068153 2024-11-20

AMBER

ETOP IBCSG Partners Foundation

Phase 2 Withdrawn
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05815186 2024-03-29

Ladarixin With Sotorasib in Advanced NSCLC - Phase II

NYU Langone Health

Phase 2 Withdrawn
Thoracic

Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation

NCT05180422 2023-10-18

A Phase I/II Study of AMG 510 in Combination With MVASI in Patients With Advanced, Unresectable or Metastatic KRAS G12C Mutant NSCLC With Asymptomatic Brain Metastasis

Criterium, Inc.

Phase 1/2 Withdrawn
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05400577 2023-07-17

Sotorasib in KRAS G12C Mutated, Resectable, Stage Ib-IIIA NSCLC

Fox Chase Cancer Center

Phase 2 Withdrawn
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡